Physician profile
Thomas A Thacker
NPI 1922251123
$1,253.99
in general payments reported to CMS, 2019-2025
23 companies · $76.68 in 2025
The $76.68 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $264 · 2021: $178 · 2022: $410 · 2023: $170 · 2024: $155 · 2025: $76.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $444.12 | 2020-2024 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $147.28 | 2021-2023 | Austedo |
| Amgen INC. | $97.48 | 2020-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $85.57 | 2020-2022 | |
| Lilly USA, LLC | $64.24 | 2020-2024 | Mounjaro |
| Alkermes, INC. | $44.45 | 2022-2023 | Vivitrol |
| Gilead Sciences, INC. | $44.16 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $42.68 | 2022 | |
| Amarin Pharma, INC. | $32.97 | 2021 | |
| Glaxosmithkline, LLC. | $32.37 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.71 | 2024 | |
| Abiomed | $20.66 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.43 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Corcept Therapeutics | $18.11 | 2023 | Korlym |
| Astrazeneca Pharmaceuticals Lp | $17.85 | 2025 | Breztri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $17.51 | 2024 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $16.75 | 2024 | Nuzyra |
| Seqirus USA INC | $16.25 | 2020 | |
| Abbvie INC. | $15.47 | 2025 | |
| Eisai INC. | $14.83 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.78 | 2025 | Caplyta |
| Mayne Pharma Commercial LLC | $13.15 | 2020 | |
| Merck Sharp & Dohme LLC | $12.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Thacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.